| Abstrakt: |
A study conducted at Massachusetts General Hospital in Boston, Massachusetts, explored the use of a targeted bispecific antibody, JNJ-67571244, in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The study aimed to determine the maximum tolerated dose, recommended phase II dose, safety, tolerability, and preliminary clinical activity of the antibody. However, the study was terminated after evaluating 10 dose-escalation cohorts and no responses were observed. The researchers concluded that the projected exposure level for JNJ-67571244 efficacy was not achieved, and therefore, the maximum tolerated dose and recommended phase II dose were not determined. [Extracted from the article] |
